Article
In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin.
The Journal of biological chemistry - 7 Jan 2005
Ho Mitchell, Kreitman Robert J, Onda Masanori, Pastan Ira
Abstract excerpt
Recombinant immunotoxin BL22, containing the Fv portion of an anti-CD22 antibody, produced complete remissions in most patients with drug-resistant hairy cell leukemia but had less activity in leukemias with low CD22 expression. Complementarity-determining region (CDR) mutagenesis is used to increase antibody affinity but can be difficult to perform successfully. We previously showed that antibodies with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
